US drug makers will no longer have to retest batches exported to the EU under a mutual recognition agreement provision expected to take effect by July 2019. It's a landmark development in industry's quest to eliminate import testing, which it says wastes time and resources. But many nations around the world still require import testing – our interactive map shows which rules apply where.
If a mutual recognition agreement between the US and the EU goes according to plan, US drug makers soon will no longer have to retest every batch of pharmaceuticals exported to the EU – a major development toward industry's goal of eliminating import testing around the world.
And the plan is on track, reaching a key milestone Nov. 1 when US recognition of eight of the EU's...